Tenet (THC) Q3 2026 Earnings Call Transcript

Tenet Healthcare reported Q3 2026 revenue of $5.631B, up 6.5% year over year, and adjusted EBITDA of $1.355B; adjusted diluted EPS was reported as $6.40 in the prepared remarks, while the article’s takeaways list $6.64. The company raised FY2026 adjusted EBITDA guidance by $195M at the midpoint to $5.05B–$5.20B and said it expects EBITDA growth in 2027 after excluding an estimated $450M of nonrecurring Conifer transition contributions. Year-to-date share repurchases totaled $1.615B for 8 million shares; management also cited 18% declines in exchange admissions and revenues as a headwind and ongoing uncertainty around Medicaid work requirements.

Analysis

THC’s beat has a quality-of-earnings discount: a meaningful portion of 2026 EBITDA is transition-related, while out-of-period Medicaid revenue also flatters reported performance. The key underwriting question is whether controllable cost savings and core demand can replace those items in 2027—not whether headline EBITDA keeps rising. A further complication is that the transcript gives conflicting adjusted EPS figures ($6.40 versus $6.64 in the article’s takeaways); verify against the release and filing before updating estimates.

Near term, the higher guide and buybacks may support sentiment, but the next 1–3 month catalyst is the Q4 disclosure of the 2027 bridge, especially exchange enrollment, Medicaid work-requirement exposure, and the sustainability of hospital cost reductions. Exchange weakness is a margin risk as well as a volume issue: lower-reimbursing or uninsured care can pressure payer mix and uncompensated-care expense. The reported 60% of admissions from expansion states makes policy changes a material watch item, though the company has not quantified the exposure to Medicaid payment reductions.

Over 6–18 months, USPI’s higher-acuity migration can support yield and asset utilization, but pricing/mix is currently doing more work than case volume; that makes growth vulnerable if elective demand softens or the migration opportunity matures. Competitors pursuing ASC acquisitions could also bid up assets, lowering returns on new investment. The contrarian point: strong cash generation and repurchases do not by themselves validate the equity if normalized earnings fall when transition benefits roll off. No valuation or post-print price data are provided, so avoid a gap-chasing entry.

Key Decisions for Investors

• Do not chase THC at the open. Consider a staged long only on post-earnings consolidation, with sizing contingent on price/valuation and confirmation that core hospital and USPI EBITDA can offset nonrecurring transition contributions.
• Use the Q4 2026 call as the primary 1–3 month catalyst check: require a quantified 2027 EBITDA bridge excluding transition items, including Medicaid supplemental-payment normalization, exchange trends, and sustainable expense savings.
• Keep an alert on Medicaid policy and exchange enrollment. Reassess the long thesis if management’s 2027 outlook implies core EBITDA contraction, uncompensated care rises materially, or same-facility USPI case volumes weaken without offsetting yield gains.
• Verify the adjusted EPS figure and reconcile reported EBITDA contributions to the SEC filing before changing earnings estimates; the supplied transcript and takeaways conflict.